Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rulonilimab plus paclitaxel and carboplatin as first-line therapy for cancer of unknown primary (CUP-005)
CTR20260176Phase 3Active
- Sponsor
- Shandong New Era Pharmaceutical
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of rulonilimab in cancer of unknown primary (CUP), sponsored by Shandong New Era Pharmaceutical. Started Jan 2026; status: active.
02
Drugs
rulonilimab
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on CTR20260176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260176.